MCID: IRD001
MIFTS: 53

Iridocyclitis

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Iridocyclitis

MalaCards integrated aliases for Iridocyclitis:

Name: Iridocyclitis 12 74 52 58 54 15 71 32
Anterior Uveitis 52 58 17
Primary Iridocyclitis 12 71

Characteristics:

Orphanet epidemiological data:

58
anterior uveitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:9383
ICD9CM 34 364.01 364.2
SNOMED-CT 67 12630008
ICD10 via Orphanet 33 H20.0 H20.1 H20.2 more
UMLS via Orphanet 72 C0022073 C0042165
Orphanet 58 ORPHA280886
UMLS 71 C0007832 C0022073 C0154909

Summaries for Iridocyclitis

MalaCards based summary : Iridocyclitis, also known as anterior uveitis, is related to fuchs' heterochromic uveitis and uveoparotid fever. An important gene associated with Iridocyclitis is DEK (DEK Proto-Oncogene), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Certolizumab pegol and Tobramycin have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the... more...

Related Diseases for Iridocyclitis

Diseases related to Iridocyclitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 934)
# Related Disease Score Top Affiliating Genes
1 fuchs' heterochromic uveitis 33.7 MRAP IL6 CYP11B1 ACE
2 uveoparotid fever 32.4 TNF ACE
3 retinal vasculitis 31.7 TNFRSF1B TNF RBP3 MRAP CD40LG CD4
4 idiopathic anterior uveitis 31.5 TNF IL6
5 glaucomatocyclitic crisis 30.8 MRAP CYP11B1
6 scleritis 30.8 TNFRSF1B TNF MRAP CRP
7 pars planitis 30.7 RBP3 MRAP HLA-B
8 interstitial nephritis 30.5 CRP CD40LG ACE
9 ocular toxoplasmosis 30.5 IL17A CD40LG
10 enthesopathy 30.4 TNFRSF1B TNF MRAP CRP
11 deep keratitis 30.4 RBP3 MRAP
12 granuloma annulare 30.3 TNFRSF1B TNF CD4
13 juvenile ankylosing spondylitis 30.3 TNFRSF1B TNF MRAP
14 anterior scleritis 30.2 TNFRSF1B MRAP CRP
15 orbital plasma cell granuloma 30.2 TNFRSF1B MRAP CRP
16 posterior uveitis 30.2 TNF RBP3 MRAP IL6
17 bartonellosis 30.2 CRP CD40LG CD4
18 parotitis 30.2 CRP CD40LG CD4
19 posterior scleritis 30.2 TNF MRAP CRP ACE
20 scarlet fever 30.2 TNF CRP CD40LG
21 neuroretinitis 30.2 MRAP CRP CD40LG CD4 ACE
22 asymptomatic neurosyphilis 30.1 CD40LG CD4
23 cervical adenitis 30.1 CRP CD40LG CD4
24 pleural empyema 30.1 CRP CD40LG CD4
25 drug reaction with eosinophilia and systemic symptoms 30.1 TNF HLA-B CRP
26 arthropathy 30.0 TNF IL6 HLA-B CRP
27 aortic valve insufficiency 30.0 MRAP CRP ACE
28 cytomegalovirus infection 30.0 TNF IL6 HLA-B
29 birdshot chorioretinopathy 29.9 RBP3 MRAP IL17A
30 miliary tuberculosis 29.9 TNF CRP CD40LG CD4
31 uveitis 29.9 TNFRSF1B TNF RBP3 IL6 IL17A IL10
32 keratoconjunctivitis 29.9 TNF IL6 IL17A
33 limited scleroderma 29.9 CRP CD40LG ACE
34 systemic autoimmune disease 29.9 IL6 IL17A CRP
35 toxoplasmosis 29.9 TNF IL6 IL10 CD40LG
36 vogt-koyanagi-harada disease 29.9 IL17A IL10 HLA-B
37 antiphospholipid syndrome 29.8 TNF CRP CD40LG
38 cryptogenic organizing pneumonia 29.8 TNF CRP CD40LG CD4
39 pustulosis of palm and sole 29.8 TNFRSF1B TNF MRAP IL17A CRP
40 blepharitis 29.8 TNF IL6 CD4
41 cat-scratch disease 29.8 CRP CD40LG CD4 ACE
42 facial paralysis 29.8 CRP CD40LG CD4 ACE
43 drug allergy 29.8 CRP CD40LG CD4 ACE
44 juvenile arthritis 29.7 IL6 IL10 DEK CRP
45 multifocal choroiditis 29.7 TNF IL10
46 juvenile rheumatoid arthritis 29.7 TNFRSF1B TNF IL6 IL10 DEK CRP
47 spotted fever rickettsiosis 29.7 TNF IL10
48 cataract 29.7 VEGFA TNF IL6 CRP CD40LG ACE
49 coccidioidomycosis 29.7 TNF IL17A CD40LG CD4
50 sympathetic ophthalmia 29.6 TNF RBP3 IL10

Graphical network of the top 20 diseases related to Iridocyclitis:



Diseases related to Iridocyclitis

Symptoms & Phenotypes for Iridocyclitis

GenomeRNAi Phenotypes related to Iridocyclitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 CD40LG IL10 IL17A TNF TNFAIP3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 ACE IL10 IL17A TNF TNFAIP3 TNFRSF1B

MGI Mouse Phenotypes related to Iridocyclitis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ACE CD4 CD40LG CRP CYP11B1 DEK
2 cardiovascular system MP:0005385 10.24 ACE CD40LG CRP CYP11B1 IL10 IL6
3 endocrine/exocrine gland MP:0005379 10.23 ACE CD4 CD40LG CYP11B1 IL10 IL17A
4 immune system MP:0005387 10.14 ACE CD4 CD40LG CRP IL10 IL17A
5 digestive/alimentary MP:0005381 10.08 CD4 IL10 IL17A IL6 TNF TNFAIP3
6 integument MP:0010771 10.07 ASPRV1 CD4 CD40LG IL10 IL17A IL6
7 mortality/aging MP:0010768 10.07 ACE CD4 CD40LG CYP11B1 IL10 IL17A
8 liver/biliary system MP:0005370 9.92 ACE IL10 IL6 MRAP TNF TNFAIP3
9 neoplasm MP:0002006 9.7 ACE DEK IL10 IL6 TNF TNFRSF1B
10 renal/urinary system MP:0005367 9.56 ACE CD40LG CYP11B1 IL17A IL6 TNFAIP3
11 respiratory system MP:0005388 9.28 IL10 IL17A IL6 MRAP NDEL1 TNF

Drugs & Therapeutics for Iridocyclitis

Drugs for Iridocyclitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Certolizumab pegol Approved Phase 4 428863-50-7
2
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
3
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
4
Difluprednate Approved Phase 4 23674-86-4 443936
5
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
6
Acyclovir Approved Phase 4 59277-89-3 2022
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
9
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
14 Anti-Allergic Agents Phase 4
15 Pharmaceutical Solutions Phase 4
16 Anti-Infective Agents Phase 4
17 Ganciclovir triphosphate Phase 4
18 Antiviral Agents Phase 4
19 valacyclovir Phase 4
20 Gastrointestinal Agents Phase 4
21 Antineoplastic Agents, Hormonal Phase 4
22 Antiemetics Phase 4
23 glucocorticoids Phase 4
24 Anti-Inflammatory Agents Phase 4
25 Ophthalmic Solutions Phase 4
26 Methylprednisolone Acetate Phase 4
27 Neuroprotective Agents Phase 4
28 Protective Agents Phase 4
29 BB 1101 Phase 4
30 Anesthetics Phase 4
31 Hormones Phase 4
32 Hormone Antagonists Phase 4
33 Adrenocorticotropic Hormone Phase 4
34 Melanocyte-Stimulating Hormones Phase 4
35 beta-Endorphin Phase 4
36
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
37
Sodium citrate Approved, Investigational Phase 3 68-04-2
38
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
39
Adalimumab Approved Phase 2, Phase 3 331731-18-1 16219006
40
Valganciclovir Approved, Investigational Phase 2, Phase 3 175865-60-8 64147
41
Phenylephrine Approved Phase 3 59-42-7 6041
42
Fluorometholone Approved, Investigational Phase 3 426-13-1 9878
43
Oxymetazoline Approved, Investigational Phase 3 1491-59-4 4636
44
Rifampicin Approved Phase 3 13292-46-1 5381226 5458213
45
Ethambutol Approved Phase 3 74-55-5 3279 14052
46
Dipivefrin Approved Phase 3 52365-63-6 3105
47
Pyrazinamide Approved, Investigational Phase 3 98-96-4 1046
48
Tropicamide Approved, Investigational Phase 3 1508-75-4 5593
49
Atropine Approved, Vet_approved Phase 3 51-55-8, 5908-99-6 174174
50
Isoniazid Approved, Investigational Phase 3 54-85-3 3767

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW) Completed NCT03020992 Phase 4 Certolizumab Pegol
2 A Randomized Clinical Trial Comparing the Intraocular Pressure Changes With the Use of Loteprednol and Dexamethasone After Pterygium Surgery Completed NCT00781300 Phase 4 Loteprednol Etabonate 0.5%;Dexamethasone 0.1%
3 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
4 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
5 A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis Recruiting NCT03626376 Phase 4 oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily;oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
6 Evaluation of DEXTENZA on the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids Not yet recruiting NCT04426734 Phase 4 Topical Prednisolone Acetate 1%
7 Prospective Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Who Are Not Well Controlled With, or Intolerant of, Topical or Systemic Corticosteroids Terminated NCT02769702 Phase 4 Acthar
8 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate
9 Herpetic Eye Disease Study (HEDS) I Unknown status NCT00000138 Phase 3 Prednisolone Phosphate;Acyclovir
10 Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT02809781 Phase 2, Phase 3 Etanercept
11 A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis. Completed NCT03131154 Phase 3 ADX-102 Ophthalmic Solution (0.5%);Vehicle of ADX-102 Ophthalmic Solution
12 Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis). Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
13 A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211;LX211;LX211
14 A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis Completed NCT01201798 Phase 3 Difluprednate 0.05% ophthalmic emulsion;Prednisolone acetate 1.0% ophthalmic suspension
15 A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis Completed NCT02517619 Phase 3 Dexamethasone Phosphate Ophthalmic Solution;Prednisolone Acetate Ophthalmic (1%)
16 A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis Completed NCT01505088 Phase 3 40 mg/mL Dexamethasone phosphate ophthalmic solution;Prednisolone Acetate (1%) Eyedrops;100 mM sodium citrate buffer solution;Placebo Eyedrops
17 Phase 3 Open-Labeled Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Severe Anterior Uveitis (Including Panuveitis). Completed NCT00407056 Phase 3 Difluprednate Ophthalmic Emulsion
18 Study of Difluprednate in the Treatment of Uveitis Completed NCT00501579 Phase 3 Difluprednate;Prednisolone Acetate
19 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
20 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
21 Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
22 Herpetic Eye Disease Study (HEDS) II Completed NCT00000139 Phase 3 Acyclovir
23 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Recruiting NCT03586284 Phase 2, Phase 3 Valganciclovir Hydrochloride;Ganciclovir Sodium;Placebo Oral Tablet;Topical placebo
24 Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA) Not yet recruiting NCT04117698 Phase 3 Antitubercular treatment (RIFATER ©);Ethambutol;RIFINAH ©
25 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis Terminated NCT00333996 Phase 2, Phase 3 Dexamethasone
26 A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis Completed NCT02406209 Phase 2 NS2;Prednisolone acetate ophthalmic suspension (1%)
27 A Randomized, Parallel Group, Double-masked, Active-controlled Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of Dexamethasone Sodium Phosphate Visulex System for the Treatment of Non-infectious Anterior Uveitis Completed NCT02309385 Phase 1, Phase 2 8% Dexamethasone Sodium Phosphate - Visulex;15% Dexamethasone Sodium Phosphate - Visulex;Prednisolone Acetate (1%) Eye Drops
28 Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Inluding Iritis, Cyclitis, Iridocyclitis, and Panuveitis). Completed NCT00405496 Phase 2 Difluprednate Ophthalmic Emulsion
29 An Open Label Exploratory Study to Assess the Safety, Tolerability and Clinical Activity of Topically Applied ESBA105 in Patients With Acute Anterior Uveitis Completed NCT00823173 Phase 2
30 A Multicenter, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Safety and Efficacy of LME636 in Patients With Acute Anterior Uveitis Completed NCT02482129 Phase 2 LME636 60 mg/mL ophthalmic solution;Dexamethasone 0.1% ophthalmic solution;LME636 Vehicle
31 The Treatment of Macular Edema Secondary to Uveitis Using Topical Interferon Gamma Completed NCT01376362 Phase 1, Phase 2 Interferon Gamma-1b
32 Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab) Completed NCT00130637 Phase 2 Daclizumab
33 A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
34 A Randomized, Double-Masked, Dose-Ranging Study to Evaluate the Safety and Tolerability of TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis. Recruiting NCT04222712 Phase 1, Phase 2 TRS01 eye drops;TRS01 eye drops
35 A Phase I/IIa Study of the Treatment of None-Infectious Anterior, Intermediate, Posterior and Panuveitis, With the Use of Dexamethasone Delivered by a Iontophoresis Device Withdrawn NCT00499551 Phase 1, Phase 2
36 Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT01420432 Phase 1
37 Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveitis Completed NCT00876434 Phase 1 Sirolimus
38 Acute Anterior Uveitis: Psychic Burden and Pain Unknown status NCT01156285
39 Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis Unknown status NCT01486693
40 Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis Unknown status NCT02879084
41 Quality of Life and Visual Function in Uveitis Patients Unknown status NCT00407316
42 Topical Ganciclovir in Patients Receiving Penetrating Keratoplasty With Cytomegalovirus Endotheliitis Unknown status NCT01359995
43 A Prospective Single-Site Non-Interventional Exploratory Study Using a Prototype Binocular Optical Coherence Tomography System for Imaging of Ocular Disease Unknown status NCT03553017
44 Does Immunogenicity Have an Influence on the Efficacy of Anti-tumor Necrosis Factor (Anti-TNF) Therapy in Patients With Ankylosing Spondylitis (AS): An Inception Cohort Study Unknown status NCT02687620
45 Observation on Effect of Anti--inflammatory and Inhibition of Recurrence on the Herpes Simplex Keratitis After Topical NSAIDs Administration Unknown status NCT03013959 Pranoprofen
46 Influência de imunomodulação Precoce Influence of Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease: a Prospective Study Unknown status NCT03399175 Early high-dose corticosteroid and immunosuppressive therapy
47 Efficacy and Adverse Effects of Cyclosporine A in the Treatment of Chronic Anterior Uveitis in Patients With Juvenile Idiopathic Arthritis Completed NCT00404482 Cyclosporine A
48 PEMF an Adjunct Therapy for Anterior Uveitis Completed NCT01154010
49 Intra-cameral Penetration of Ganciclovir Following Topical Administration of 0.15% Ganciclovir Gel (VIRGAN©) for CMV Anterior Uveitis / Endotheliitis Completed NCT01647529 Ganciclovir
50 Retinal Optical Coherence Tomography and Multifocal Electroretinogram; Establishing Normal Ranges Related to Age and Reproductive Factors; With the Use of Anti-inflammatory Medications;In Uncomplicated Anterior Uveitis; Anatomy and Function. Completed NCT00476593 Diclofenac;Dexamethasone

Search NIH Clinical Center for Iridocyclitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Scopolamine
Scopolamine Hydrobromide
Tropicamide

Genetic Tests for Iridocyclitis

Anatomical Context for Iridocyclitis

MalaCards organs/tissues related to Iridocyclitis:

40
Eye, Endothelial, T Cells, Retina, Testes, Neutrophil, Bone

Publications for Iridocyclitis

Articles related to Iridocyclitis:

(show top 50) (show all 4503)
# Title Authors PMID Year
1
Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene. 54 61
9058666 1997
2
Analysis of the role of palmitoleic acid in acute anterior uveitis. 61
32422526 2020
3
Spectral domain optical coherence tomography findings of patients with ankylosing spondylitis. 61
32533454 2020
4
Racial Differences in Clinical Features and Comorbidities in Ankylosing Spondylitis in the United States. 61
31474592 2020
5
Ultra-widefield fundus fluorescein angiography findings in patients with ankylosing spondylitis experiencing uveitis. 61
32488588 2020
6
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. 61
32157555 2020
7
Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci. 61
32492107 2020
8
A case report of pseudo-exfoliation syndrome with prolonged corneal epithelial regeneration because of erlotinib-induced unilateral corneal ulcer and anterior uveitis. 61
32483873 2020
9
Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. 61
32556494 2020
10
About 3 cases of post-acute retinopathy of chikungunya fever. 61
32505386 2020
11
Factors Predictive of Remission of Chronic Anterior Uveitis. 61
31932091 2020
12
A plethora of manifestations following a Mycoplasma pneumoniae infection: a case report. 61
30767713 2020
13
A Cross-Sectional Online Survey Identifies Subspecialty Differences in the Management of Pediatric Cataracts Associated with Uveitis. 61
32157612 2020
14
Tubulointerstitial nephritis and uveitis (TINU) syndrome: a review. 61
31719109 2020
15
Clinical utility of aqueous humor polymerase chain reaction and serologic testing for suspected infectious uveitis: a single-center retrospective study in South Korea. 61
32560636 2020
16
Uveitis Induced by Biological Agents Used in Cancer Therapy. 61
32546073 2020
17
Anterior uveitis secondary to intraocular fiber from a hair enhancement product. 61
32258823 2020
18
Triamcinolone acetonide loaded-cationic nano-lipoidal formulation for uveitis: Evidences of improved biopharmaceutical performance and anti-inflammatory activity. 61
32143010 2020
19
A retrospective histologic study of 140 cases of clinically significant equine ocular disorders. 61
32207378 2020
20
Study of onchocerciasis-related visual impairment in North Kivu province of the Democratic Republic of Congo in Africa. 61
32317473 2020
21
A case of severe flare reaction observed in HLA B27 associated acute anterior uveitis. 61
32448152 2020
22
Evaluation of changes in choroidal vascularity during acute anterior uveitis attack in patients with ankylosing spondylitis by using binarization of EDI-optical coherence tomography images. 61
32434070 2020
23
Pediatric Uveitis in a Referral Center in North Part of Turkey. 61
32463707 2020
24
Causes of Hypertensive Anterior Uveitis in Thailand. 61
31697590 2020
25
Tubulointerstitial Nephritis and Uveitis Syndrome: Characterization of Clinical Features. 61
32463299 2020
26
Treatment of Cytomegalovirus Anterior Uveitis at a North American Tertiary Center With Oral Valganciclovir. 61
32068609 2020
27
5-year longitudinal study of clinical and patient-reported outcomes in acute anterior uveitis. 61
32405048 2020
28
Viral Acute Anterior Uveitis: Clinical Signs Useful for Differential Diagnosis. 61
32407185 2020
29
Anterior Uveitis Due to Intracameral Moxifloxacin: A Case Report. 61
32469689 2020
30
Characteristics and Clinical Outcomes of Hypertensive Anterior Uveitis. 61
31020885 2020
31
Retinal Microcirculation Defects on OCTA Correlate with Active Inflammation and Vision in Vogt-Koyanagi-Harada Disease. 61
32407159 2020
32
Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. 61
31409649 2020
33
Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical rimexolone 1. 61
32318939 2020
34
Clinical characteristics and treatment of spontaneous chronic corneal epithelial defects (SCCEDs) with diamond burr debridement. 61
32379378 2020
35
Epidemiology of 2000 Chinese uveitis patients from Northeast China. 61
32424058 2020
36
Unilateral acute anterior uveitis is associated with ipsilateral changes in the tear fluid proteome that involves the LXR/RXR pathway. 61
32458144 2020
37
In Vivo Analysis and Comparison of Anterior Segment Structures of Both Eyes in Unilateral Herpetic Anterior Uveitis. 61
32469669 2020
38
What Does Human Leukocyte Antigen B27 Have to Do with Spondyloarthritis? 61
32340698 2020
39
Characterization and Management of Inflammatory Eye Disease in Patients with Hidradenitis Suppurativa. 61
32255701 2020
40
Acanthamoeba keratitis in Australia: demographics, associated factors, presentation and outcomes: a 15-year case review. 61
31554948 2020
41
Development of Acute Vogt-Koyanagi-Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma. 61
31161956 2020
42
Propionibacterium Acnes Endophthalmitis Following Baerveldt Glaucoma Device Implantation. 61
32341322 2020
43
Bilateral Acute Anterior Uveitis during Chemotherapy with Cytosine Arabinoside with a Total Cumulative Dose of 24 000 mg for Myelodysplastic Syndrome. 61
32330986 2020
44
Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany. 61
32293540 2020
45
The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings. 61
32250731 2020
46
Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: comparing the soluble receptor to monoclonal antibodies in a large observational cohort. 61
32336278 2020
47
An Algorithm for the Diagnosis of Behçet Disease Uveitis in Adults. 61
32286112 2020
48
Acute Bilateral Anterior Uveitis following Cyclophosphamide/ Bortezomid/Dexamethasone (CyBorD) Protocol in a Newly Diagnosed Multiple Myeloma Patient with Concomitant Use of Zoledronic Acid. 61
32286130 2020
49
Incidence and Risk Factors for Blindness in Uveitis: A Nationwide Cohort Study from 2002 to 2013. 61
32293927 2020
50
Pattern and Outcome of Uveitis in a Tertiary Military Hospital in Thailand. 61
31009267 2020

Variations for Iridocyclitis

Expression for Iridocyclitis

Search GEO for disease gene expression data for Iridocyclitis.

Pathways for Iridocyclitis

Pathways related to Iridocyclitis according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 VEGFA TNFRSF1B TNFAIP3 TNF IL6 IL17A
2
Show member pathways
13.26 TNFRSF1B TNF IL6 IL17A IL10 CD40LG
3
Show member pathways
13.2 VEGFA TNFRSF1B TNF IL6 IL17A IL10
4
Show member pathways
12.89 VEGFA TNFRSF1B TNF IL6 HLA-B CD4
5
Show member pathways
12.66 TNFRSF1B TNFAIP3 TNF IL6 CD40LG
6
Show member pathways
12.62 TNFRSF1B TNFAIP3 TNF CD40LG CD4
7
Show member pathways
12.59 TNFRSF1B TNF IL10 CD40LG CD4
8
Show member pathways
12.56 TNF IL6 IL17A IL10 CD4
9
Show member pathways
12.54 TNF IL6 IL17A IL10 CD4
10
Show member pathways
12.5 TNF IL6 IL17A IL10 CD40LG CD4
11 12.4 TNFRSF1B TNFAIP3 TNF IL17A IL10 CD40LG
12 12.3 TNF IL6 HLA-B CD4
13
Show member pathways
12.3 VEGFA TNF IL6 IL17A IL10 HLA-B
14
Show member pathways
12.29 TNFAIP3 TNF IL6 IL17A
15
Show member pathways
12.29 TNFRSF1B TNF IL6 IL10
16
Show member pathways
12.22 TNF IL6 IL17A IL10 HLA-B
17 12.21 TNFRSF1B TNFAIP3 TNF CD40LG
18 12.14 VEGFA TNF IL6 IL10
19 11.92 TNF IL6 IL10 CD4
20 11.9 TNFRSF1B TNFAIP3 TNF IL6
21 11.81 VEGFA TNF IL6 IL17A
22
Show member pathways
11.77 TNFRSF1B TNF CD40LG
23 11.73 TNF IL6 IL10
24
Show member pathways
11.71 TNFRSF1B TNF CD40LG
25 11.71 TNF IL17A IL10 CD4
26
Show member pathways
11.68 TNF IL6 IL17A IL10 CD4
27 11.66 TNF IL6 IL10 CD4
28
Show member pathways
11.56 VEGFA TNF IL6 CD40LG
29 11.37 TNF IL6 IL10 CD40LG
30 11.34 TNF IL6 IL10
31
Show member pathways
11.32 TNFRSF1B TNF IL10
32 11.31 TNFRSF1B TNF IL6 IL10
33 11.3 TNF IL6 IL10
34 11.26 TNF IL6 IL17A
35 11.25 TNFRSF1B TNFAIP3 TNF
36 11.16 VEGFA TNFRSF1B TNF IL6 IL17A IL10
37 10.98 TNF IL6 CRP
38 10.92 TNF IL6 IL10 CD4

GO Terms for Iridocyclitis

Cellular components related to Iridocyclitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 VEGFA TNF RBP3 IL6 IL17A IL10
2 external side of plasma membrane GO:0009897 9.55 TNF IL17A CD40LG CD4 ACE
3 extracellular region GO:0005576 9.32 VEGFA TNFRSF1B TNF RBP3 IL6 IL17A

Biological processes related to Iridocyclitis according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 VEGFA TNF IL6
2 response to glucocorticoid GO:0051384 9.74 TNF IL6 IL10
3 cellular response to lipopolysaccharide GO:0071222 9.72 TNFRSF1B TNFAIP3 TNF IL6 IL10
4 positive regulation of T cell proliferation GO:0042102 9.71 IL6 CD40LG CD4
5 inflammatory response GO:0006954 9.7 TNFRSF1B TNFAIP3 TNF IL6 IL17A CRP
6 negative regulation of interleukin-6 production GO:0032715 9.63 TNFAIP3 TNF IL10
7 regulation of neuroinflammatory response GO:0150077 9.6 TNFRSF1B IL6
8 response to molecule of bacterial origin GO:0002237 9.59 TNFAIP3 IL10
9 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.58 TNF IL17A
10 positive regulation of JAK-STAT cascade GO:0046427 9.58 TNF IL6 IL10
11 endothelial cell apoptotic process GO:0072577 9.56 TNF IL10
12 neutrophil mediated immunity GO:0002446 9.55 IL6 ACE
13 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.54 TNF IL6 IL17A
14 negative regulation of cytokine production involved in immune response GO:0002719 9.52 TNF IL10
15 regulation of immunoglobulin secretion GO:0051023 9.51 TNF CD40LG
16 cytokine-mediated signaling pathway GO:0019221 9.5 VEGFA TNFRSF1B TNF IL6 IL17A IL10
17 negative regulation of cytokine secretion involved in immune response GO:0002740 9.49 TNF IL10
18 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.48 VEGFA ACE
19 receptor biosynthetic process GO:0032800 9.43 TNF IL10
20 negative regulation of lipid storage GO:0010888 9.43 TNF IL6 CRP
21 immune response GO:0006955 9.28 TNFRSF1B TNF IL6 IL17A IL10 HLA-B

Molecular functions related to Iridocyclitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 VEGFA TNFAIP3 TNF NDEL1 MRAP CRP
2 cytokine activity GO:0005125 9.1 VEGFA TNF IL6 IL17A IL10 CD40LG

Sources for Iridocyclitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....